North China Pharmaceutical announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for cefradine approved and issued by the State Drug Administration. The registration number is Y20250000180. The notice is valid until November 4, 2031. The drug has a total R&D expenditure of 7.245,600 yuan, and production and marketing can be arranged after passing on-site GMP compliance checks. This approval further complements the company's API products, enriches the product line, and will not have a significant impact on the company's current business performance.
Zhitongcaijing · 2d ago
Share
Listen to the news
North China Pharmaceutical announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for cefradine approved and issued by the State Drug Administration. The registration number is Y20250000180. The notice is valid until November 4, 2031. The drug has a total R&D expenditure of 7.245,600 yuan, and production and marketing can be arranged after passing on-site GMP compliance checks. This approval further complements the company's API products, enriches the product line, and will not have a significant impact on the company's current business performance.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending